Navigation Links
VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
Date:3/12/2009

Pioneering study uses quantitative imaging endpoints from MRI analyses

ROCHESTER, N.Y., March 12 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, today announced that BioSyntech Inc., a Canadian medical device company based in Laval, Quebec, has reached its enrollment goal in the Canadian-European pivotal clinical trial for its cartilage repair device (BST-CarGel(R)) and will now focus on quantitative measures to determine enhanced efficacy compared to the surgical technique called microfracture.

Historically, clinical trials for cartilage-related therapies have used pain as the primary endpoint. In the BST-CarGel(R) study, however, VirtualScopics is providing blinded data analysis of quantitative magnetic resonance imaging (MRI) which will allow BioSyntech to demonstrate BST-CarGel's potential for affecting the quantity and quality of the repaired cartilage as their primary endpoint.

"We are very pleased to be working with BioSyntech on this unique Canadian-European pivotal trial," said Jeff Markin, VirtualScopics' president and chief executive officer. He further added, "The quantitative nature of these endpoints offers the opportunity to design cartilage repair trials that may be smaller or shorter in comparison to conventional designs which use more qualitative or subjective endpoints. We look forward to providing BioSyntech the critical information they need to demonstrate the effectiveness of their product."

Chief Scientific Officer at BioSyntech, Dr. Matthew Shive, commented, "VirtualScopics' experience in incorporating standardized, yet advanced, imaging into international, multi-center clinical trials has allowed us to conduct what we believe to be the first trial of its kind in cartilage repair. Strategically, their expertise permitted us to focus on the key parameters of repair which are most prominent following treatment with BST-CarGel."

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.

About BioSyntech

BioSyntech is a medical device company specialized in the development, manufacturing and commercialization of advanced biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's platform technology is a family of hydrogels called BST-Gel(R), some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offer beneficial properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. For additional information, visit www.biosyntech.com

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the backlog and new customer awards in 2008 and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

    CONTACT:  Molly Henderson
              Chief Business and Financial Officer
              500 Linden Oaks
              Rochester, New York 14625
              (585) 249.6231


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Breast Imaging Technology Targets Hard-to-Detect Cancers
2. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
3. September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging
4. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
5. CRi Announces New Maestro(TM) EX In Vivo Imaging System with Improved Performance and an Affordable Price
6. Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimers
7. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
8. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
9. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
10. First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System
11. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016  Labvantage Lx, a newcomer to ... male sexual enhancement product, EnduramenT. Setting a new ... with a patented biomedical breakthrough molecule that promotes ... compound responsible for many biological functions including erectile ... Forgoing the use of prescription medications, scientists ...
(Date:2/8/2016)... , Feb. 8, 2016  Echo Therapeutics, ... device company focused on non-invasive continuous glucose ... today announced that it will host a ... 17, 2015 at 9:00 a.m. Eastern Time ... its corporate strategy, advancements in its CGM ...
(Date:2/8/2016)... 2016 In a historic vote among its members this weekend, ... medical cannabis cultivation facility and dispensary on tribal land near ... as a provider for patients in the state,s Medical Cannabis Program. ... a provider for patients in the state,s Medical Cannabis Program. ... the project and pursue designation from the State of New ...
Breaking Medicine Technology:
(Date:2/8/2016)... Los Angeles, CA (PRWEB) , ... February 08, 2016 , ... ... autism conference held annually in this country. The AutismOne 2016 Conference, which is being ... the truth they often won’t hear elsewhere about helpful interventions and causes of chronic ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... the latest techniques and the most minimally invasive approaches. , Women who have ... after menopause. Other risk factors include surgery to the pelvic floor, connective tissue ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information to ... combines three elements to cut the cost of providing employee healthcare benefits by ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... With ... and easily add warm color grades to their footage. A LUT is a Lookup ... pixel's color to the corresponding color indicated by the table. By manipulating each pixel, ...
Breaking Medicine News(10 mins):